Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021896 | 1.00 | MAPT (0.57) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL23612029 | 1.00 | MAPT (0.57) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL31703634 | 0.88 | MAPT (0.47) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL110185 | 0.87 | MAP4K4 (0.59) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL29546457 | 0.87 | MAP4K4 (0.59) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL2067786 | 0.86 | ALDH1A1 (0.55) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL31257432 | 0.85 | MAPT (0.54) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL25353652 | 0.85 | ALDH1A1 (0.54) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL29318821 | 0.85 | MAPT (0.54) | MAPTALDH1A1LMNAMAP4K4CKS1B | |
| SCHEMBL31129803 | 0.84 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAMAP4K4CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4245758-A2 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | Xynomic Pharmaceuticals, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | XYNOMIC PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111818924-B | Crystalline salts of B-RAF kinase inhibitors | 徐诺药业公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3700530-B1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | XYNOMIC PHARMACEUTICALS, INC. | 2020-09-10 | — | — | US | disclosed |
| EP-3700530-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | Xynomic Pharmaceuticals, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889684-B2 | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| EP-1943243-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7652015-B2 | Suppression cytokines , tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080269244-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| EP-1943243-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053394-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | MAPT 2885/4885ALDH1A1 98/4885LMNA 1598/4885 |
| US-20200283433-A1 | CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | MAPT 2719/4885ALDH1A1 2930/4885LMNA 3492/4885 |
| US-20080269244-A1 | Kinase Inhibitors | MAP3K1, MAP3K20, MAP3K19 | MAPT 2487/4885ALDH1A1 2938/4885LMNA 3146/4885 |
| US-11753409-B2 | Crystalline salts of a B-RAF kinase inhibitor | BRAF, RAF1, ARAF | MAPT 2719/4885ALDH1A1 2930/4885LMNA 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.